Consensus Statement Regarding the Application of Biogen to Health Canada for Approval of Aducanumab

Alzheimer’s disease is a major cause of morbidity and mortality. Currently, there are no disease-modifying pharmacotherapies for this condition. Aducanumab, an amyloid beta-directed monoclonal antibody that targets aggregated forms of amyloid-beta in the brains of people with Alzheimer’s disease, ha...

Descripción completa

Detalles Bibliográficos
Autores principales: Chertkow, Howard, Rockwood, Kenneth, Hogan, David B., Phillips, Natalie, Montero-Odasso, Manuel, Amanullah, Shabbir, Black, Sandra, Bocti, Christian, Borrie, Michael, Feldman, Howard, Freedman, Morris, Hsiung, Robin, Kirk, Andrew, Masellis, Mario, Nygaard, Haakon, Rajji, Tarek, Verret, Louis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Canadian Geriatrics Society 2021
Materias:
Commentaries
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8629494/
https://www.ncbi.nlm.nih.gov/pubmed/34912492
http://dx.doi.org/10.5770/cgj.24.570

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8629494/
https://www.ncbi.nlm.nih.gov/pubmed/34912492
http://dx.doi.org/10.5770/cgj.24.570

Ejemplares similares